Condition: Tuberculosis, Pulmonary · Sponsor: University of Cape Town
This is a proof-of-concept phase IIB, double-blind, randomized, placebo-controlled trial to evaluate the safety and efficacy of 40 mg atorvastatin to reduce persistent lung inflammation after successful TB treatment completion in HIV-infected and HIV-uninfected adults measured by PET/CT.
This description comes directly from the study's public registry record.
Friedrich Thienemann, MD · +27 21 406 6358 · friedrich.thienemann@uct.ac.za
Sandra Mukasa, MD · +27 21 406 6358 · sandra.mukasa@uct.ac.za
Always discuss trial participation with your own doctor first.
| General Medicine & Global Health, Cape Heart Institute, Faculty of Health Sciences, University of Cape Town | Observatory, WC, South Africa | Recruiting |
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT04147286